Lisa Ricciardi, president and CEO of Cognition Therapeutics was recently a guest on Benzinga's All-Access. Cognition ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

Several recent studies have suggested HRT is a risk factor in various conditions, notably Alzheimer's - now UK boffins have ...

A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...

Nov. 19, 2024 — Common cardiovascular drugs are linked to a lower risk of dementia in older age, according to a new ... Earlier Diabetes Diagnosis Linked to Dementia Risk Nov. 19, 2024 ...

Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Unhappily, oxybutynin hydrochloride, tolterodine tartrate and solifenacin succinate – the three linked to dementia – are considered the most effective drugs for treating overactive bladder.

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...

Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...

The world’s largest study of proteins circulating the human body will begin in the UK this month, with the aim of pinpointing ...